A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
High urgency

Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I

Detected July 16, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

DEA places four synthetic cannabinoids (4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, MMB-FUBICA) into Schedule I, making them illegal to manufacture, distribute, or possess without DEA authorization.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, API/contract manufacturers, and compounding outsourcing facilities (503B) that handle or may encounter these substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon publication in the Federal Register (May 1, 2026). Immediate compliance required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

These four substances are now classified as Schedule I controlled substances, with no accepted medical use and high abuse potential.

Who it affects

All pharmaceutical manufacturers, API/contract manufacturers, and compounding outsourcing facilities (503B) that handle or may encounter these substances.

What you must do

Immediately cease any production, distribution, or possession of these substances; review inventory and supply chains; notify DEA if any are present; and ensure no further handling without a Schedule I research registration.

Deadline

Effective upon publication in the Federal Register (May 1, 2026). Immediate compliance required.

Source: https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)